Bridging Cancer and COVID‐19: The Complex Interplay of ACE2 and TMPRSS2

Cancer Medicine, Journal Year: 2025, Volume and Issue: 14(7)

Published: March 27, 2025

ABSTRACT The coronavirus disease 2019 (COVID‐19) pandemic presents heightened risks for cancer patients, who are more susceptible to severe acute respiratory syndrome 2 (SARS‐CoV‐2) infection and outcomes due immunosuppression from both the malignancy anticancer therapies. This review investigates dual roles of angiotensin‐converting enzyme (ACE2) transmembrane serine protease (TMPRSS2) in SARS‐CoV‐2 among patients. ACE2, vital entry receptor SARS‐CoV‐2, is overexpressed certain tumors such as colon adenocarcinoma, renal carcinomas, pancreatic lung potentially increasing viral susceptibility. Paradoxically, ACE2 also exhibits tumor‐suppressive properties by inhibiting angiogenesis modulating tumor microenvironment, leading improved patient prognoses some cancers like breast cancer. TMPRSS2, essential entry, shows decreased expression several but acts a prognostic biomarker prostate cancers. illustrates complexity therapeutically targeting TMPRSS2 their contrasting progression entry. We analyze levels relation immune cell infiltration outcomes, propose personalized therapeutic strategies. Furthermore, we underscore necessity multidisciplinary approaches, integrating antiviral treatments with therapies tailoring interventions based on individual molecular profiles. approach medicine seeks enhance treatment results better manage patients have contracted SARS‐CoV‐2.

Language: Английский

Hypericin impedes M2 macrophage polarization and protects against Hepatocellular carcinoma

Molecular Immunology, Journal Year: 2025, Volume and Issue: 181, P. 160 - 168

Published: March 29, 2025

Language: Английский